126 related articles for article (PubMed ID: 36094487)
1. Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine.
Dumchev K; Kiriazova T; Riabokon S; Shost A; Parrish C; Shapoval A; Germanovych M; Penner J; Beste J; Puttkammer N
J Acquir Immune Defic Syndr; 2022 Oct; 91(2):197-209. PubMed ID: 36094487
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
[TBL] [Abstract][Full Text] [Related]
4. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
[TBL] [Abstract][Full Text] [Related]
5. Patient-Reported Treatment Satisfaction and Quality of Life Among People Living with HIV Following the Introduction of Dolutegravir-Based ART Regimens in Ukraine.
Hong C; Puttkammer N; Riabokon S; Germanovich M; Shost A; Parrish C; Shapoval A; Dumchev K
AIDS Behav; 2022 Apr; 26(4):1056-1073. PubMed ID: 34515881
[TBL] [Abstract][Full Text] [Related]
6. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
Facha W; Tadesse T; Wolka E; Astatkie A
PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
8. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
[TBL] [Abstract][Full Text] [Related]
9. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.
Modongo C; Wang Q; Dima M; Matsiri O; Kgwaadira B; Rankgoane-Pono G; Shin SS; Zetola NM
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):111-115. PubMed ID: 31335593
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
13. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir based therapy showed CD4
Gebremedhin T; Aynalem M; Adem M; Geremew D; Aleka Y; Kiflie A
Sci Rep; 2024 Feb; 14(1):3297. PubMed ID: 38331983
[TBL] [Abstract][Full Text] [Related]
15. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
16. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
Jamieson L; Serenata C; Makhubele L; Sokhela S; Mashabane N; Akpomiemie G; Johnson LF; Venter WDF; Meyer-Rath G
AIDS; 2021 Dec; 35(Suppl 2):S173-S182. PubMed ID: 34848584
[TBL] [Abstract][Full Text] [Related]
17. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
[TBL] [Abstract][Full Text] [Related]
18. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
19. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
20. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
